New report shows how osteoarthritis costs are being managed

Which is more cost-effective-surgery for osteoarthritis (OA) of the knee or viscosupplement/hyaluronic acid (HA) products-and how are employers managing the costs of these treatments? These are questions addressed in a new report commissioned by Ferring Pharmaceuticals. The 68-page report covers the views of managed care pharmacy and medical directors, orthopedic surgeons, rheumatologists, and others. The Parsippany, N.J., firm explained that the report is timely because OA, the second most common diagnosis and leading cause of disability, is on the rise. A free copy of the report can be obtained by calling Ferring at 1-(888) 337-7464.

Click here to see more articles from Drug Topics Daily News.

To go to the Drug Topics homepage, click here.